Transforming growth factor beta 1 selectively regulates early murine hematopoietic progenitors and inhibits the growth of IL-3-dependent myeloid leukemia cell lines by unknown
TRANSFORMING GROWTH FACTOR (31 SELECTIVELY
REGULATES EARLY MURINE HEMATOPOIETIC
PROGENITORS AND INHIBITS THE GROWTH OF
IL-3-DEPENDENT MYELOID LEUKEMIA CELL LINES
By JONATHAN R. KELLER,' CHARLES MANTEL,$ GARWIN K. SING,1
LARRY R. ELLINGSWORTH,4 SANDRA K. RUSCETTI,II
AND FRANCIS W. RUSCETTI1
From the *Biological Carcinogenesis Development Program, Program Resources, Inc.,
National Cancer Institute, Frederick Cancer Research Facility, Frederick, Maryland 21701;
the $Laboratory of Molecular Immunoregulation, Biological Response Mothers Program,
Division of Cancer Treatment, National Cancer Institute, Frederick Cancer Research Facility,
Frederick, Maryland 21701; the §Collagen Corp., Palo Alto, California, and the
IlLaboratory of Genetics, National Cancer Institute, National Institutes of Health,
Bethesda, Maryland 20205
The identification of stimulatory factors for hematopoiesic cells has greatly enhanced
our understanding of the regulation of hematopoiesis (1, 2) . While these factors
augment cellular proliferation and differentiation, less is known about those factors
that might be involved in either negative growth regulation or the regulation of
homeostasis of hematopoiesis. A new family of polypeptide growth factors that regulate
cell growth and differentiation has recently been identified which includes transforming
growth factor type R (TGFR),' inhibin, Mfillerian inhibitory substance, and
decapentaplegic gene complex (3). TGFR activity was originally identified in the
supernatants of transformed fibroblasts by its ability to induce the anchorage-
independent growth (transformed phenotype) of NRK 49F fibroblasts in soft agar
(4, 5). TGF-(3 was initially purified to homogeneity from human platelets (6) and
was subsequently found to be produced by many normal tissues (7). TGF-0 is a 25-
kD disulfide-linked homodimeric protein whose sequence is highly conserved, with
a single amino acid difference between mouse and man (8). Recently, a second form
of TGFp was identified in bovine bone called CIF-13 (9), now known as TGF(i2,
that shares significant homology to the first type of TGF(3, now known as TGF(31
(10). TGF-R1 has been shown to be multifunctional in its influence on cellular
proliferation by also acting as a growth inhibitor ofmany different cell types including
hepatocytes, keratinocytes and embryo fibroblasts (7, 11).
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In cells of the immune system, TGF-(31 has been shown to have antiproliferative
effects on both IL-2-dependent T lymphocyte proliferation (12) as well as IL-1-mediated
thymocyte proliferation (13). In other immunocompetent cells, TGF-(31 suppresses
the secretion of Ig by B cells (14) and blocks the cytotoxic activity of NK cells (15).
Immunohistochemical studies using antibodies to the NH2 terminus of TGF-(31
demonstrated that TGF-0l is locally produced by cells in centers of active
hematopoiesis (fetal liver and bone marrow) and lymphopoiesis (Hassall's corpuscles)
(16). In addition, the relative yield of TGF(31 from normal tissue varies 100-fold,
with the presence of large amounts in cortical bone and human platelets (9, 17),
suggesting that the biological significance of TGF-(31 in vivo may be in tissue repair
and bone formation (7, 18).
Since TGF-0 is produced in local areas of hematopoiesis, it may play a role in
regulating hematopoietic cell growth and differentiation. Thus, experiments were
designed to examine the effects of TGF-(31 on normal murine hematopoietic
progenitors as well as their leukemic counterparts including both IL-3-dependent
and -independent myeloid leukemic cells.
Materials and Methods
Animals.
￿
BALB/c mice were obtained from the animal production area of the NCI-
Frederick Cancer Research Facility (Frederick, MD).
Growth Factors.
￿
Murine IL-3 was purified to homogeneity from WEHI-3 cell superna-
tants using previously described procedures (19). Purified recombinant murine granulo-
cyte/macrophage colony-stimulating factor (GM-CSF) was supplied by Immunex Corpora-
tion, Seattle, WA. Purified humanrecombinant granulocyte (G)-CSF was supplied by Lawrence
Souza, Amgen Corp. Purified murine recombinant IL-4 (IL-4/BSFI) was purchased from
Genzyme Corp., Boston, MA. Human urinary erythropoietin (Epo) was purchased from
Amgen Corp. Murine CSF1 was obtained from the conditioned media of L929 cells. Bovine
TGF-(31 was purified to homogeneity using previously described procedures (9). Antiserum
to TGF-51 has been previously characterized (16) and was used as described in the figure
legends.
Cell Lines.
￿
The cell linesFDC-Pl (20), 32D-c123 and B6SutA (21) were derived from long-
term in vitro mouse bone marrow cultures, while NFS-60 and DA-3 (22) were derived from
the preleukemic spleen from mice infected with murine leukemia viruses. These lines repre-
sent phenotypically early hematopoietic progenitors by morphology, cytochemistry, and sur-
face markers. The other cell lineswere maintained in RPMI 1640 in 10% FCS and included
DS19 (23), TP3 (24), P388D1, J774A.1, WEHI-3B, and P815 obtained from the American
Type Culture Collection, Rockville, MD.
Bone Marrow Proliferation Assay.
￿
Bone marrow was aspirated from the femurs of BALB/c
mice with RPMI 1640, then washed twice and resuspended in RPMI 1640 containing 10%
FCS and seeded into 96-well microtiter plates (Costar, Cambridge, MA) at 10' cells in 100
wl of medium. Proliferation was assessed after 72 h of incubation at 37°C in 5% C02 with
an overnight pulse of 1 gCi [3H]TdR (6.7 Ci/mmol) (New England Nuclear, Boston, MA) .
Cell cultures were harvested with a multiple sample harvester onto glassfiberfilters. Individual
filters were placed in 2 ml of PCS scintillation fluid (Amersham Corp., Arlington Heights,
IL) and radioactivity was assessed by liquid scintillation counting.
Cell Proliferation Assays.
￿
IL-3-dependent or -independent cell lines used in proliferation
assays were washed twice in serum-free RPMI 1640 and plated into 96-well microtiter plates
at a density of 104 cells in 100 wl of RPMI 1640 containing 5 0 /c FCS, unless otherwise indi-
cated. Cultures were incubated 48 h at 37°C, 5% C02 with a 6-h pulse of [3H]TdR and
harvested as described above for bone marrow.
Splenocyte Proliferation Assay.
￿
Spleen cells from normal or phenylhydrazine hydrochloride
treated mice, and splenocytes from mice infected with the polycythemia-inducing strain ofKELLER ET AL.
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the spleen focus forming virus (SFFV) were obtained as previously described (25). Cells were
cultured in the presence or absence of Epo at 37 °C at a concentration of 4 x 106 cells/ml
in 0.1 ml of RPMI 1640, 10% FCS, 0.1 mM 2-ME for 24 h with a 2-h pulse of [3H]TdR,
and they were harvested as described above for the bone marrow.
Soft Agar Colony Formation.
￿
A modification of the method of Stanley et al. (26) was used
to measure colony formation of bone marrow cells. Briefly, BALB/c bone marrow cells were
suspended in 1 ml RPMI 1640, 10% FCS, 0.1 mM 2-ME in 0.3% Seaplaque agarose (Rock-
land, ME) with a source of CSF and incubated in 35-mm Lux petridishes (Miles Laborato-
ries Inc., Naperville, IL) at 37°C in 5% C02 and scored for colony growth (CFU) at the
indicated times. For GM colony numbers, all colonies >50 cells are counted. For the growth
of multipotential colonies, granulocyte, erythroid, megakaryocyte, and macrophage (CFU-
GEMM), cultures were additionally supplemented with hemin and Epo. In the CFU-GEMM
assay, only the colonies that contain all four lineages are counted, even though other colonies
are present. For the formation of erythroid colonies, CFU-E, cells were cultured for 2 d in
a plasma clot system (27) in the presence of 0.5 U/ml Epo and the clots were stained with
benzidine and examined microscopically for benzidine-positive colonies.
Results
Effect of TGF--/31 on Factor-induced Murine Bone Marrow Proliferation.
￿
Normal bone
marrow cells are known to proliferate in the presence of a number ofgrowth factors.
IL-3 promotes the differentiation of multipotent stem cells as well as more lineage-
restricted hematopoietic progenitors, while othergrowth factors such as G-CSF, GM-
CSF, and Epo are known to act upon cellslater in the various hematopoietic lineages
and exhibit relatively restricted lineage specificity (1, 2). To test the effects of TGF
(31 on the proliferation of bone marrow cells in the presence of various factors, freshly
aspirated cells were used in a standard proliferation assay. As shown in Fig. 1, II:-3-
driven proliferation of bone marrow cells was inhibited by TGF01 in a close-
dependent manner with an ED-50 of 0.05 ng/ml (2 pM). The same effect was ob-
served whether the assay was performed with a low dose of IL-3 (5 U/ml) or saturating
amounts of IL-3 (50 U/ml). Kinetic experiments demonstrated that maximum inhi-
bition was observed after the cells had been incubated for 48 h with TGFR1 . The
antiproliferative effects were not due to cytotoxicity since TGF-(31 did not affect the
viability of cultured bone marrow cells (data not shown).
In contrast, TGF01 showed no effects on G-CSF or GM-CSFdriven prolifera-
tion in the presence of increasing concentrations of TGF[31 (Fig. 1) . Thus, TGF(31
showed a differential effect on CSFinduced normal bone marrow proliferation. In
addition, not all of the bone marrow proliferation stimulated by IL-3 is inhibitable
by TGFR1.
Effect of TGF-,Q1 on Murine Hematoiboietic Colony Formation.
￿
Under conditions of
limiting cell number, soft agar assays provide a convenient means to measure the
clonal proliferation as well as the differentiation potential of hemaotpoietic progen-
itors. Therefore, soft agar colony assays were used to determine the extent of TGFD1
inhibition within particular cell lineages. TGFDl suppressed IL-3-induced CFU-GM
colony formation using 10 ng/ml TGFR1, a concentration that maximally inhibited
[3H]TdR incorporation in the bone marrow proliferation assay (Table I). While
overall colony formation was consistently inhibited by TGFD, small clusters (<20
cells) and a few colonies were also consistently observed. This effect was observed
when 5 U/ml or 50 U/ml of IL-3 was used. TGF(31 inhibition of IL-3-induced CFU-
GM colonies occurred in a dose-dependent manner with an ED-50 of5-10 pM (Fig. 2).740
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In agreement with proliferation data, TGF(31 had no inhibitory effect on G-CSF
or GM-CSFpromoted hematopoietic cell colony formation, although an increased
colony number was obtained in some experiments with GM-CSF (Table I). When
adherent bone marrow cells were removed by absorbance to plastic petri dishes be-
fore plating in the assay, increased colony formation observed with GM-CSF was
decreased (data not shown).20
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TABLE I
Effect of TGF-01 on Hematoboietic Colony Formation in Soft Agar
* Colonies were scored after six to eight days incubation. Means t SEM are
representative of three separate experiments .
" Cultures were supplemented with' 10 ng/ml TGF-/31 .
Thus, TGFR1 differentially regulates colony formation in that it is a potent in-
hibitor ofIL-3-induced colony formation but not ofGM-CSF orG-CSFpromoted
colony formation.
Effect of TGF-01 on Multipotential Colony Formation.
￿
IL-3 promotes the prolifera-
tionanddifferentiation insoft agarofmany hematopoietic lineages from bonemarrow
and in the presence of Epo can induce the proliferation and differentiation of one
ofthe earliest in vitro colonies, CFU-GEMM, a colony consisting offour hemato-
poietic lineages (1, 2). Colony assays to measure CFU-GEMM formation were set
up to determine ifTGF-01 had an effect on the formation ofthese earliest hemato-
poietic colonies. In the absence of TGFp1, between five and eight CFU-GEMM
colonieswere scored in three separate experiments, while in the presence ofTGF-01
no CFU-GEMM colonies were detected (Table II). This result is also depicted in
the transmission photomicrograph in Fig.3, where in the absence ofTGF01 (panel
A) a multilineage colony with cell types from the four lineages is observed, while
in the presence ofTGF0l only small clusters ofdifferentiated granulocytes or mac-
rophages were obtained. Therefore, TGF-01 blocks the proliferation and differenti-
ation ofearly hematopoietic progenitors (CFU-GEMM) while allowing clusters (<20
cells) of more differentiated progeny to develop, which explains why IL-3-induced
bone marrow proliferation is not completely inhibited by TGF(31.
-50 Ulml
10-1 10-1 10-1 1 10
TOFB nglml
KELLER ET AL.
￿
741
FIGURE 2.
￿
Dose response ofTGFpl inhibition
of IL-3-induced bone marrow cell soft agar colony
formation. Bone marrow cells were plated into
soft agarandassayed according to the procedures
in the Materials andMethods and TGF-01 was
diluted at the indicated concentrations into me-
dium containing aconstant amount of IL-3, 50
U/ml ( "). Arrow indicates the IL-3-induced
colony formation in the absence of TGFS1.
Stimulator
Number
+TGF-011
of colonies*
-TGF-01
None 0 0
IL-3(50 U/ml) 5 t 3 52 ± 5
IL-3 (5 U/ml) 0 6 t 3
GM-CSF (I ng/ml) 387 t 11 113 ± 12
GM-CSF (0.1 ng/ml) 56 f 4 27 f 12
G-CSF (100 U/ml) 20 ± 4 25 f 4742
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TABLE II
Effect of TGF-01 on IL-3-dependent Multipotential Hematopoietic
Colony Formation
Stimulator
￿
TGF-01' CFU-GEMM1
Epo (2 U/ml)
￿
-
￿
0
IL-3 (50 U/ml) + Epo (2 U/ml)
￿
-
￿
5-8
IL-3 (50 U/ml) + Epo (2 U/ml)
￿
+
￿
0
Cultures were grown in the presence ( + ) or absence ( - ) of 1 ng/ml TGF-pl .
1 Colony formation was scored after 10 d. These data are representative of three
separate experiments.
Effect of TGF-01 on ErythroidDevelopment.
￿
Two factors are needed to promote the
growth oferythroid developmentin CFU-GEMM colonies, namely IL-3, which affects
the growth and differentiation of early progenitor cells, and Epo, which stimulates
the proliferation and terminal differentiation of late erythroid progenitors. Since
the data on CFU-GEMM formation indicated that TGFpl could inhibitthe prolifer-
ation and differentiation of early erythroid progenitor cells, we were interested in
whetheror not it wouldalso inhibitthe Epo-driven later stages of erythroidcell growth.
As shown in Fig. 4, Epo promotes the proliferationof spleen cellsfrom phenylhydra-
zine-treated mice (90% are erythroid precursors) in a dose-dependent manner. In
the presence of saturating amounts of Epo, TGF(31 had no inhibitory effect when
tested over a wide range of concentrations. In addition, TGF-01 had no effect on
Epo-induced late erythroid colony formation (CFU-E) (Table III). Therefore, TGF-
01 appears to suppress the proliferation and differentiation of early uncommitted
hematopoietic progenitor cells but is inactive on later precursor cells that are com-
mitted to a particular lineage.
Effect of TGF-01 on Factor-dependent and -independent MyeloidLeukemic Cell Lines.
￿
Since
the data suggest that TGFR1 might play a role in regulating the growth and differen-
tiation of early but not late hematopoietic progenitor populations, we examined a
variety offactor-dependent progenitor cell lines representing leukemic clonal popu-
lations or early myeloid cells blocked in early stages ofdifferentiation based on their
phenotype, function, and morphology (22). As shown in Fig. 5, TGFQ1 inhibits
IL-3-induced proliferation ofthe NFS-60 cell line using either 0.5 U/ml or 50 U/ml
of IL-3. Data from several experiments demonstrate that the inhibition is dose-
dependent with an ED-50 of 5-15 pM. Using a polyclonal antiserum to TGF-(31,
the inhibitory effects of TGF-01 on IL-3-driven proliferation were effectively neu-
tralized in a dose-dependent manner, while normal rabbit serum showed no effect
(Fig. 6), demonstrating the action of TGF-01 could be specifically neutralized. In
addition, GM-CSFinduced and G-CSFinduced proliferationof NFS-60 cells is also
inhibited by TGFPI in a dose-dependent manner (panels B and C) with ED-50s
of 5-15 pM. NFS-60 cells also provide a convenient means to test two other growth
factors, CSF1 and BSF-1/IL-4. As shown in Fig. 7, the proliferation of NFS-60 cells
in the presence of saturating amounts of each factor was inhibited by TGFR1 in
dose-dependent manner with ED-50s of 5-10 pM for CSF1 and IL-4.
Inhibition of proliferation in the presence of TGF-01 was consistently observed
among other factor dependent cell lines regardless of their derivation with similar
results (Table IV). In addition to the factor-dependent cell lines, a factor-independentKELLER ET AL .
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FIGURE 3 .
￿
Transmission photomicrographs of IL-3-induced multipotential(CFU-GEMM) bone
marrow colonies in soft agar in the absence (A) or presence (B) of TGF-01 .
myelomonocytic cell line, WEHI-3B, was also inhibited in a dose-dependent manner
by TGF-(31 . TGF(31 did not induce the differentiation of those lines that were in-
hibited . In contrast, growth of factor independent cell lines of erythroid, macro-
phage and mast cell lineages, blocked late in their respective lineages, were not in-
hibited by TGF-R1 .744
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Discussion
The production ofblood cellsis regulated by cells which produce stimulatory and
inhibitory molecules, as well as those cells that can respond to these factors (1, 2).
Evidence presented here suggests that TGFal may serve a critical regulatory role
in murine hematopoiesis in that it is a potent negative regulator of early but not
late hematopoietic growth and differentiation. Specifically, TGFR1 inhibits early IL-
3-induced bone marrow progenitor cell proliferation and colony growth in soft agar,
but has no suppressive influence on the proliferation and differentiation induced
by other later acting hematopoietic growth factors, G-CSF, GM-CSF, and Epo. In
addition, while colony formation is significantly inhibited in cultures containing IL-
3 and TGF-(31, clusters and small colonies of differentiated myeloid cells of one lin-
eage were consistently seen . This is consistent with bone marrow proliferation data
that show some IL-3-induced proliferation occurs in the presence of TGF(31. Also,
TGF(31 selectively blocks the growth and differentiation of early multipotential pro-
genitor cells (IL-3-regulated CFU-GEMM), a component of which is representa-
tive of early erythroid differentiation, while it has no effect on the late stages oferythroid
differentiation (Epo-regulated CFU-E). Thus, the inhibitory effect of TGF-(31 on
hematopoietic cells appears to be a function of the state of cellular differentiation,
TABLE III
Effect of TGF-01 on Erythropoietin-induced Colony Formation
Number of CFU-E'
Erythroid colonies were scored after 48 h according to the assay described in
the procedures.
1 Cultures were supplemented with 1 ng/ml TGF-01 .
§ Normal, phenylhydrazine-treated, and Friend virus-infected splenocytes were
obtained as described in the Materials and Methods. These data are represen-
tative of three separate experiments.
Cell source + TGF-p 1$ -TGF-p1
Normal splenocytes§ 64 60
Phenylhydrazine splenocytes§ 1,684 1,635
FVP splenocytes§ 2,298 2,340ISO
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FIGURE 5. Dose response of
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￿
tion. NFS-60 cells were seeded
into microtiter wells at a den-
sity of 105 cells/ml and har-
vested according to the proce-
dures outlined in theMaterials
and Methods. TGFpl was di-
luted at theindicated concentra-
tionsinto medium containinga
constant amount of IL-3, 50
U/ml ("), or .5 U/ml IL-3 (A)
in panelA; and 100ng/ml GM-
CSF(0)or 0.1 ng/mlGM-CSF
(A) in panel B; and 200 U/ml
G-CSF (") or 2 U/ml G-CSF
-BKC
￿
(A) in panelC. Arrows indicate
1°-'
￿
IL-3-, GM-CSF, and G-CSF
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10-~
induced proliferation in theab-
senceof TGFpl or background
proliferation (BKG).
such that, as erythroid and myeloid cells undergo maturation there is a point at which
they become insensitive to the inhibitory effect of TGF(31 . The resistance to the in-
hibitory action of TGF(i1 could be a result of a change in the affinity or number
of TGF01 receptors. Therefore, experiments have been initiated to determine both
the biological effect as well as the receptor status on purified populations of more
differentiated hematopoietic progenitors.746
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While the soft agar colony assay measures the clonal growth and differentiation
of hematopoietic progenitors, it is not possible under these circumstances to rule
out that the action of an exogenous factor might be due to the indirect effects on
other subpopulations. However, since receptors for TGF-01 are present on all cell
types (7), to conclusively prove that TGF-a1 is acting directly, one would need a
pure population of progenitor cells. A reasonable approach would be to examine
clonal hematopoietic growth factor cell lines. The results with NSF-60 cells, which
are clonal as demonstrated by the presence of a rearranged c-myb locus in all cells
(28), suggests that TGF-(31 can act directly on hematopoietic cell progenitors.
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FIGURE 6.
￿
Neutralization by antiTGF-a1 of the TGF-
01-induced inhibition of NFS-60 cell proliferation.
Normal rabbit serum (O) or polyclonal antiTGF-01
rabbit serum (X) were incubated with 10 ng/ml TGF-
01 at the indicated dilutions in 50 wl media at 37°C.
After 1 h of incubation, NFS-60 cells were added to a
final concentration of 105/ml in 50 U/ml IL-3 andcells
were harvested as described in the Materials andMeth-
ods. Arrows indicate IL-3-induced proliferation in the
absence ofTGF01, or background proliferation (BKG).
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FIGURE 7. Dose response of
TGF-01 on CSF-1 and IL-4-in-
duced proliferation of NFS-60
cells. NFS-60 cells were plated
into microtiter wells at a density
of 105/ml and harvested accord-
ing to procedures in the Ma-
terials andMethods. CSF-1 (A)
andIL-4 (C) werediluted at the
indicated concentrations into
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TABLE IV
Efect of TGF-01 on Leukemic Cell Lines
" Cell proliferation assays were performed according to the procedures in the
Materials and Methods.
TGF-pl wasdiluted into cell proliferation assays to generate adose response
curve starting at a concentration of 40 ng/ml. The range represents the maxi-
mum percent inhibition obtained from the dose-response curves from three
separate experiments .
Nonetheless, experiments have been designed to support the direct action of TGF
(31 by testing IL-3-induced Thy-1 + murine progenitors obtained by FAGS (29) .
Since both murine and human leukemic cells have been shownto maintain growth
factor responsiveness in vitro, a loss of negative growth control might contribute
to a preleukemic state by permitting the unrestrained growth of factor-dependent
leukemic clones. Such a process might result, for example, in the out-growth of IL-
3-dependent myeloid leukemic progenitor cells. Our results indicate, however, that
the growth of IL-3-dependent leukemias in vitro is inhibited by TGF-01 and that
this effect is seen regardless of the growth factor used to signal proliferation. It is
possible that additional events (abrogation of factor dependence) may be required
to escape negative regulation. Alternatively, others (7, 11, 30, 31) found that the human
melanoma cell line A549 produces an inactive or latent form of TGFR1, while it
is potently inhibited by exogenous TGF(31, thus leading to the proposal that a le-
sion in TGF-(31 activation might have contributed to the evolution of this cancer.
Our laboratory has recently found that while IL-3-dependent myeloid leukemic cells
express messenger RNA for TGF-01 (manuscript in preparation), no TGF-P1 bio-
activity in the supernatant has been detected. Thus, experiments are underway to
determine if the TGF-01 protein is produced and whether it is secreted in a latent
or inactive form which might result in the breakdown of negative autocrine growth
control.
In summary, TGFR1 may serve a critical regulatory role in murine hematopoi-
esis in that it is a potent negative regulator ofearly but not late hematopoietic differen-
tiation and proliferation. Thus, in normal cell populations, TGF-(31 is a differential
regulator of growth factor-promoted hematopoietic differentiation. In addition, TGF
(31 inhibits the growth of differentiated-arrested factor-dependent and -independent
leukemic myelomonocytic cells but not thoseleukemias blocked late in their lineage.
The capacity to selectively inhibit early marrow cell and leukemic cell prolifera-
Cell line' Lineage
IL-3
dependence
TGF-01 percent
inhibition)
NFS-60 Myeloid + 60-70
DA-3 Myeloid + 80-90
32D-cl23 Myeloid + 70-80
FDC-P1 Myeloid + 80-90
B6SutA Myeloid + 65-75
P388D1 Macrophage - 0
J774A.1 Macrophage - 0
WEHI-3 Myelomonocytic - 80-90
TP-3 Erythroid - 0
DS19 Erythroid - 0
P815 Mast cell - 0748￿
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tion could have clinical applications. A variety ofhematopoietic tumors may be respon-
sive in vivo to TGF(31 inhibition, which could be a useful adjunct to cytoreductive
combination chemotherapy. In addition, if TGF-/31 growth-arrested marrow stem
cells are less sensitive to the toxic effects of chemotherapeutic agents, TGFQ 1 may
be a valuable component of cancer treatment programs that have dose-limiting my-
elotoxicity. Experiments to evaluate these potential therapeutic applications of TGF-
(31 are underway.
Summary
Transforming growth factor (31 (TGF-(31) has been shown to be associated with
active centers of hematopoiesis and lymphopoiesis in the developing fetus. There-
fore, the effects of TGFQ1 on mouse hematopoiesis were studied. TGF~l is a po-
tent inhibitor of IL-3-induced bone marrow proliferation, but it does not inhibit
the proliferation induced by granulocyte/macrophage, colony-stimulating factor (CSF),
granulocyte CSF, and erythropoietin (Epo). TGF0l also inhibits IL-3-induced mul-
tipotential colony formation of bone marrow cells in soft agar, which includes early
erythroid differentiation, while Epo-induced terminal differentiation is unaffected.
In addition, IL-3-induced granulocyte/macrophage colonies were inhibited; how-
ever, small clusters of differentiated myeloid cells were consistently seen in cultures
containing IL-3 and TGF(31. Thus, TGF-al selectively inhibits early hematopoi-
etic progenitor growth and differentiation but not more mature progenitors. TGF-
(31 is also a potent inhibitor of IL-3-dependent and -independent myelomonocytic
leukemic cell growth, while the more mature erythroid and macrophage leukemias
are insensitive. Therefore, TGF(31 functions as a selective regulator of differentiating
normal hematopoietic cells, and suppresses myeloid leukemic cell growth.
The authors would like to thank Drs. D. L. Longo and J. J . Oppenheim for helpful discus-
sions and critical review of this manuscript.
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